A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma

NCT00762255 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: Vorinostat
DRUG: Bevacizumab
DRUG: Irinotecan

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]